watching development of Mab12

[Guest guest]

Tried to find past discussion here, but nothing when I searched the

archives, as I'm new to the group.

Wondering if anyone else is watching the Mab12 studies ? Keli

Will Xolair Become Obsolete in the Treatment of Allergies?

http://www.glgroup.com/News/Will-Xolair-Become-Obsolete-in-the-

Treatment-of-Allergies--25461.html

A high-affinity monoclonal anti-IgE antibody for depletion of IgE and

IgE-bearing cells.

Original article

http://pt.wkhealth.com/pt/re/algy/abstract.00000381-200806000-

00007.htm;jsessionid=J16JGxQWhtVhjqgpV9ppxf6L3RTf1fr1XzhdFCkZNJbLGgpgS

92T!418234175!181195628!8091!-1

Next-Generation Xolair (omalizumab) sounds pretty good

http://www.glgroup.com/News/Next-Generation-Xolair-(omalizumab)-

sounds-pretty-good-25671.html

June 18, 2008

Analysis of: Investigational Anti-IgE Antibody Promising as

Extracorporeal Allergy Therapy | www.medscape.com

This analysis is solely the work of the author. It has not been

edited or endorsed by GLG.

Analysis By: Engler, MD

Physician, The Allergy Clinic

Implications: This drug seems much more effective at reducing free-

IgE levels than is Xolair. Overall, Xolair has given many patients a

tremendous improvement in their quality of life, but it hasn't

fulfilled many of its promises. ly, some of Xolair's benefits

are disappointing, particularly in the 40 or 50% of patients who use

it without achieving great results. In particular, Xolair patients

who are on Advair 500/50 can sometimes get down to Advair 250/50, but

it's been difficult tapering them to lower doses of inhaled

corticosteroids.

Analysis: One of the problems with Xolair is that it an antibody to

all IgE. Future generations of monoclonal antibodies directed

against IgE will be designed to act only against dust mite IgE. Or

cat IgE.

Or, if we're really lucky one day, against PEANUT IgE. The study

that was published on Xolair and peanuts showed that those allergic

to peanuts increased their tolerance from 1/2 of one peanut to 9

peanuts.

Though a discernable difference, it is not exactly what we were

hoping for. Another company, Tanox, was working on another anti-IgE

specifically to fight peanut allergy. According to a Texas Monthly

article from the mid-1990's, Genentech (DNA) stole Tanox's anti-IgE

ideas, then ending up buying Tanox after wearing them down in court.

And then Genentech shut down the research involving Tanox's unique

approach to anti-IgE, and made no further plans to investigate peanut

allergy with Xolair.

OK, back to this improved anti-IgE. If an asthma biotech drug is

going to cost a couple thousand dollars a month, it's reasonable for

us to expect it to work pretty well; either significantly improving

quality of life, reducing visits to the E.R., and reducing the need

for potentially harmful high-dose inhaled corticosteroids.

The classic Xolair study showed that you could decrease an

asthmatic's use of inhaled steroids. But guess what? The steroid

they had patients using in that study was beclomethasone. That's

right, they didn't use fluticasone or budesonide or any of the high-

potency inhaled steroids. They used the equivalent of a Model T.

Instead of a modern Mercedes-Benz or BMW, they used an old Ford Model

T. They had to do that because they wanted the results to be

clinically significant, with a p-value <.05.

So, in summary, we all know that Xolair is the first of many biotech

drugs to come out of the gate to treat severe asthma. While it has

been helpful in many patients, the market is ready for new, improved

versions of anti-IgE. Especially one that needs to be used exactly

one time, and one time only---Xolair must be used once or twice per

month, indefinitely.

[Guest guest]

Thank you for the information.  It is interesting. I'm not scientific enough to

understand anything except they are working on some sort of medicine/treatment

to give just once instead of once or twice a month indefinitely.

 

Adah

From: kelijeans <kelijeans@...>

Subject: [ ] watching development of Mab12

Date: Tuesday, December 2, 2008, 7:39 AM

Tried to find past discussion here, but nothing when I searched the

archives, as I'm new to the group.

Wondering if anyone else is watching the Mab12 studies ? Keli

Will Xolair Become Obsolete in the Treatment of Allergies?

http://www.glgroup. com/News/ Will-Xolair- Become-Obsolete- in-the-

Treatment-of- Allergies- -25461.html

A high-affinity monoclonal anti-IgE antibody for depletion of IgE and

IgE-bearing cells.

Original article

http://pt.wkhealth. com/pt/re/ algy/abstract. 00000381- 200806000-

00007.htm;jsessioni d=J16JGxQWhtVhjq gpV9ppxf6L3RTf1f r1XzhdFCkZNJbLGg pgS

92T!418234175! 181195628! 8091!-1

Next-Generation Xolair (omalizumab) sounds pretty good

http://www.glgroup. com/News/ Next-Generation- Xolair-(omalizumab) -

sounds-pretty- good-25671. html

June 18, 2008

Analysis of: Investigational Anti-IgE Antibody Promising as

Extracorporeal Allergy Therapy | www.medscape. com

This analysis is solely the work of the author. It has not been

edited or endorsed by GLG.

Analysis By: Engler, MD

Physician, The Allergy Clinic

Implications: This drug seems much more effective at reducing free-

IgE levels than is Xolair. Overall, Xolair has given many patients a

tremendous improvement in their quality of life, but it hasn't

fulfilled many of its promises. ly, some of Xolair's benefits

are disappointing, particularly in the 40 or 50% of patients who use

it without achieving great results. In particular, Xolair patients

who are on Advair 500/50 can sometimes get down to Advair 250/50, but

it's been difficult tapering them to lower doses of inhaled

corticosteroids.

Analysis: One of the problems with Xolair is that it an antibody to

all IgE. Future generations of monoclonal antibodies directed

against IgE will be designed to act only against dust mite IgE. Or

cat IgE.

Or, if we're really lucky one day, against PEANUT IgE. The study

that was published on Xolair and peanuts showed that those allergic

to peanuts increased their tolerance from 1/2 of one peanut to 9

peanuts.

Though a discernable difference, it is not exactly what we were

hoping for. Another company, Tanox, was working on another anti-IgE

specifically to fight peanut allergy. According to a Texas Monthly

article from the mid-1990's, Genentech (DNA) stole Tanox's anti-IgE

ideas, then ending up buying Tanox after wearing them down in court.

And then Genentech shut down the research involving Tanox's unique

approach to anti-IgE, and made no further plans to investigate peanut

allergy with Xolair.

OK, back to this improved anti-IgE. If an asthma biotech drug is

going to cost a couple thousand dollars a month, it's reasonable for

us to expect it to work pretty well; either significantly improving

quality of life, reducing visits to the E.R., and reducing the need

for potentially harmful high-dose inhaled corticosteroids.

The classic Xolair study showed that you could decrease an

asthmatic's use of inhaled steroids. But guess what? The steroid

they had patients using in that study was beclomethasone. That's

right, they didn't use fluticasone or budesonide or any of the high-

potency inhaled steroids. They used the equivalent of a Model T.

Instead of a modern Mercedes-Benz or BMW, they used an old Ford Model

T. They had to do that because they wanted the results to be

clinically significant, with a p-value <.05.

So, in summary, we all know that Xolair is the first of many biotech

drugs to come out of the gate to treat severe asthma. While it has

been helpful in many patients, the market is ready for new, improved

versions of anti-IgE. Especially one that needs to be used exactly

one time, and one time only---Xolair must be used once or twice per

month, indefinitely.

[Guest guest]

whatever that med is can not come too soon for many of us. and hopefully

insurance will cover it. i am tired of being sick. having sinus surgery on

friday.

Adah Voigt <asthmatic50@...> wrote: Thank you

for the information. It is interesting. I'm not scientific enough to understand

anything except they are working on some sort of medicine/treatment to give just

once instead of once or twice a month indefinitely.

Adah

From: kelijeans <kelijeans@...>

Subject: [ ] watching development of Mab12

Date: Tuesday, December 2, 2008, 7:39 AM

Tried to find past discussion here, but nothing when I searched the

archives, as I'm new to the group.

Wondering if anyone else is watching the Mab12 studies ? Keli

Will Xolair Become Obsolete in the Treatment of Allergies?

http://www.glgroup. com/News/ Will-Xolair- Become-Obsolete- in-the-

Treatment-of- Allergies- -25461.html

A high-affinity monoclonal anti-IgE antibody for depletion of IgE and

IgE-bearing cells.

Original article

http://pt.wkhealth. com/pt/re/ algy/abstract. 00000381- 200806000-

00007.htm;jsessioni d=J16JGxQWhtVhjq gpV9ppxf6L3RTf1f r1XzhdFCkZNJbLGg pgS

92T!418234175! 181195628! 8091!-1

Next-Generation Xolair (omalizumab) sounds pretty good

http://www.glgroup. com/News/ Next-Generation- Xolair-(omalizumab) -

sounds-pretty- good-25671. html

June 18, 2008

Analysis of: Investigational Anti-IgE Antibody Promising as

Extracorporeal Allergy Therapy | www.medscape. com

This analysis is solely the work of the author. It has not been

edited or endorsed by GLG.

Analysis By: Engler, MD

Physician, The Allergy Clinic

Implications: This drug seems much more effective at reducing free-

IgE levels than is Xolair. Overall, Xolair has given many patients a

tremendous improvement in their quality of life, but it hasn't

fulfilled many of its promises. ly, some of Xolair's benefits

are disappointing, particularly in the 40 or 50% of patients who use

it without achieving great results. In particular, Xolair patients

who are on Advair 500/50 can sometimes get down to Advair 250/50, but

it's been difficult tapering them to lower doses of inhaled

corticosteroids.

Analysis: One of the problems with Xolair is that it an antibody to

all IgE. Future generations of monoclonal antibodies directed

against IgE will be designed to act only against dust mite IgE. Or

cat IgE.

Or, if we're really lucky one day, against PEANUT IgE. The study

that was published on Xolair and peanuts showed that those allergic

to peanuts increased their tolerance from 1/2 of one peanut to 9

peanuts.

Though a discernable difference, it is not exactly what we were

hoping for. Another company, Tanox, was working on another anti-IgE

specifically to fight peanut allergy. According to a Texas Monthly

article from the mid-1990's, Genentech (DNA) stole Tanox's anti-IgE

ideas, then ending up buying Tanox after wearing them down in court.

And then Genentech shut down the research involving Tanox's unique

approach to anti-IgE, and made no further plans to investigate peanut

allergy with Xolair.

OK, back to this improved anti-IgE. If an asthma biotech drug is

going to cost a couple thousand dollars a month, it's reasonable for

us to expect it to work pretty well; either significantly improving

quality of life, reducing visits to the E.R., and reducing the need

for potentially harmful high-dose inhaled corticosteroids.

The classic Xolair study showed that you could decrease an

asthmatic's use of inhaled steroids. But guess what? The steroid

they had patients using in that study was beclomethasone. That's

right, they didn't use fluticasone or budesonide or any of the high-

potency inhaled steroids. They used the equivalent of a Model T.

Instead of a modern Mercedes-Benz or BMW, they used an old Ford Model

T. They had to do that because they wanted the results to be

clinically significant, with a p-value <.05.

So, in summary, we all know that Xolair is the first of many biotech

drugs to come out of the gate to treat severe asthma. While it has

been helpful in many patients, the market is ready for new, improved

versions of anti-IgE. Especially one that needs to be used exactly

one time, and one time only---Xolair must be used once or twice per

month, indefinitely.